- Home
- NEGG vs ADCT Comparison
NEGG vs ADCT Comparison
Compare NEGG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- ADCT
- Stock Information
- Founded
- NEGG 2001
- ADCT 2011
- Country
- NEGG United States
- ADCT Switzerland
- Employees
- NEGG N/A
- ADCT N/A
- Industry
- NEGG Other Specialty Stores
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- ADCT Health Care
- Exchange
- NEGG Nasdaq
- ADCT Nasdaq
- Market Cap
- NEGG 122.3M
- ADCT 398.2M
- IPO Year
- NEGG 2010
- ADCT 2020
- Fundamental
- Price
- NEGG $43.98
- ADCT $3.31
- Analyst Decision
- NEGG
- ADCT Strong Buy
- Analyst Count
- NEGG 0
- ADCT 6
- Target Price
- NEGG N/A
- ADCT $7.80
- AVG Volume (30 Days)
- NEGG 2.1M
- ADCT 644.5K
- Earning Date
- NEGG 08-29-2025
- ADCT 11-06-2025
- Dividend Yield
- NEGG N/A
- ADCT N/A
- EPS Growth
- NEGG N/A
- ADCT N/A
- EPS
- NEGG N/A
- ADCT N/A
- Revenue
- NEGG $1,313,127,000.00
- ADCT $77,246,000.00
- Revenue This Year
- NEGG N/A
- ADCT $12.71
- Revenue Next Year
- NEGG N/A
- ADCT $6.59
- P/E Ratio
- NEGG N/A
- ADCT N/A
- Revenue Growth
- NEGG N/A
- ADCT 15.73
- 52 Week Low
- NEGG $3.32
- ADCT $1.05
- 52 Week High
- NEGG $137.84
- ADCT $3.97
- Technical
- Relative Strength Index (RSI)
- NEGG 45.14
- ADCT 54.71
- Support Level
- NEGG $33.52
- ADCT $3.20
- Resistance Level
- NEGG $48.90
- ADCT $3.38
- Average True Range (ATR)
- NEGG 9.73
- ADCT 0.17
- MACD
- NEGG -3.66
- ADCT 0.00
- Stochastic Oscillator
- NEGG 19.48
- ADCT 49.09
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).